Sundial is aware of an online article involving a commercial relationship with another Licensed Producer. There were factual inaccuracies in the article. While Sundial cannot comment on specific customer agreements due to contractual confidentiality, we can confirm that this isolated immaterial matter is being resolved between Sundial and the Licensed Producer. There is no impact on Q2 financial reporting and we anticipate that the impact on Q3 earnings will be negligible. Sundial follows strict Good Production Practices (GPP) in accordance with all Health Canada standards. Our company also uses standard provisions for potential returns which is consistent with industry practice.
Sundial is committed to producing safe, innovative and high-quality products.
Sundial Delivers Quarterly Net Revenue of $33.5 Million Representing 74% Sequential GrowthRead More
Sundial has announced that it has changed the time for its third quarter 2019 earnings conference call and webcast.Read More
Sundial is pleased to announce that it has been added to The Cannabis ETF, which trades on the New York Stock Exchange (NYSE).Read More